

nexus/ag



QUARTERLY REPORT
from the 01st of January to
30th of September 2016

Letter to Our Stockholders

Dear Stockholders

The NEXUS team can also report continued very positive business development and new, future-oriented targets! We are pleased about this success, especially against the background of the strong figures of last year and the significant investment and integration expenses that we had in recent months.

With increased sales of approx. 10 % and a higher earnings before taxes and interest of about 19 %, we were again able to continue our growth course connected with continual improvement of our results in the first nine months of 2016. The number of new orders received also developed very well during this time despite fewer bid invitations. We were able to acquire new overall customers for NEXUS in Germany, Switzerland and France and received three significant orders for the „managed services“ area. As we have previously reported, winning the tender of the Hirslanden Group, Switzerland, for introduction of a new group-wide Radiology Information System (RIS) is of particular importance for us. This provided proof that our NEXT GENERATION technology has the potential to change understanding of healthcare software significantly. This is of particular importance for us, because the NEXT / NEXUS program is the focus of our product strategy. NEXT / NEXUS is a synonym for our new software generation NEXUS / NEXT GENERATION, which is more than a further technical development: It is the implementation of completely intuitive user prompting. Long menu trees or intensive software training sessions are a thing of the past. The NEXT GENERATION software provides process-oriented screen layouts that users can easily navigate and which can be customized. We are taking the new and bold step to design our software completely process-oriented and user-related.


Highlights 3rd Quarter – 2016

Company development


- + Strong development of sales in the first nine months
- + Substantial growth in all regions
- + Hirslanden Group, Switzerland, opts for the NEXUS / RIS
- + Acquisition of a market leader for documentation of sterile goods in Germany (IBH, Kassel)

Our „internationalization“ strategy project also developed very positively. We acquired the leading provider of sterile goods documentation in Europe with the acquisition of IBH Datentechnik GmbH, Kassel, in September 2016. The company with

Development of Group Sales (9 months) in KEUR 2008-2016



Development of Group Earnings before Interest and Taxes (9 months) KEUR 2008-2016




approx. 20 employees is strengthening our already very good market position in this very important healthcare segment. At the same time, it provides a convincing complement to our product portfolio and the possibility to integrate sterilization processes fully into our clinical information system (NEXUS / HIS). This acquisition is just as much part of our internationalization strategy as is the acquisition of SISinf, SL, Sabadell, Spain, which we completed in July. We were able to acquire a company in this case, which occupies a prominent position in major hospitals in Catalonia and which can benefit considerably from NEXUS products. We are pursuing our strategy consistently with that. We use e-health expertise from the different European countries to improve our products and services continuously.

We have development and sales locations in Germany, Switzerland, Austria, France, the Netherlands and Spain in the meantime and are active in many countries via partners. The exchange of know-how, software and processes between national companies works increasingly better in the meantime, and we are able to adopt „best practice“ solutions from the respective health systems.

Dear Shareholders, the first nine months have been very successful. We have achieved good figures and developed our future potential for success. This includes first and foremost our NEXT / NEXUS program, but also the further internationalization of our business base and collaboration with a medical device manufacturer. However, our goal of developing NEXUS in an internationalized structure into the leading European provider of e-health solutions remains a great challenge. We must not overlook the challenges and risks in our rapidly evolving business model. However, we are aware of these challenges and would like to thank you, dear stockholders, for your trust.

Warm regards,

Dr. Ingo Behrendt
CEO



Financial Highlights

for the 3rd Quarter 2016 und 2015

	30/09/2016	30/09/2015	Changes
	KEUR	KEUR	%
Sales	77,308	69,949	10.5
Sales Healthcare Software	70,905	64,189	10.5
Sales Healthcare Service	6,403	5,760	11.2
Domestic sales	39,380	34,239	15.0
Sales in foreign countries	37,928	35,710	6.2
Group earnings before interest and taxes (EBIT)	7,571	6,341	19.4
Consolidated surplus	6,533	6,270	4.2
EBITA	9,608	8,674	10.8
EBITDA	14,596	13,382	9.1
Cash flow from current business transactions	15,356	13,823	11.1
Net income per share (undiluted / diluted) in EUR	0.40 / 0.40	0.40 / 0.40	0.0
Share price (closing price 30 September 2016, XETRA) in EUR	18,43	17,90	3.0
Capitalization of software developments	3,989	3,542	12.6
Depreciation	7,025	7,041	-0.2
Balance Sheet Total	144,662	129,691 ¹⁾	11.5
Net Liquidity	20,235	18,082	11.9
Equity Capital	93,500	89,060 ¹⁾	5.0
Equity Ratio in %	64,6	68,7 ¹⁾	-6.0
Employees (as of the cut-off date)	902	788	14.5

¹⁾ Cut-off date 31 December 2015

Interim Annual Report

Report about the Profit, Financial and Asset Situation

NEXUS Group sales increased from KEUR 69,649 to KEUR 77,308 (+10.5 %) in the first nine months of the year 2016.

As a result, the sustained steady good sales development of the NEXUS Group of recent years could be continued in the first nine months of 2016. Sales increased from KEUR 64,189 to KEUR 70,905 (+10.5 %) in the Healthcare Software Division. Sales increases of +11.2 % were achieved in the Healthcare Service Division (9M-2016: KEUR 6,403; 9M-2015: KEUR 5,760). Strong sales in this division were achieved via new „managed service“ contracts.

There is also a uniform picture within the national organizations. We were able to increase sales in Germany by 15.0 % to KEUR 39,380 (9M-2015: KEUR 34,239). In international business, we recorded sales of KEUR 37,928 from January to September 2016 compared to KEUR 35,710 in the previous year (+6.2 %). We have had substantial sales increases in the Netherlands (+13.7 %). We consolidated NEXUS Nederland starting from February in the previous year. In Switzerland sales increased +3.5 %.

Sales effects from exchange rate fluctuations were only significant in the case of Swiss francs. A negative sales effect of KEUR 220 resulted there. The average exchange rate of the Swiss franc of SFR 1,0936 on 30 September 2016 was above of the average price on 31 December 2015 (SFR 1,0808). The special income of KEUR 34 (9M-2016) from exchange rate gains in the reporting period was substantially below that of the previous year (9M-2015: KEUR 619).

The earnings before interest and taxes (EBIT) also developed very strongly. KEUR 7,571 (9M-2016) were recorded and consequently an increase of 19.4 % compared to the previous year (9M-2015: KEUR 6,341). A value of KEUR 9,608 was achieved in EBITA and consequently was 10.8 % above the value of previous year (9M-2015: KEUR 8,674). EBITDA amounts to KEUR 14,596, which represents an increase of 9.1 % compared to the previous year (9M-2015: KEUR 13,382).


The cash flow from ongoing business transactions also developed positively. At KEUR 15,356, the cash flow was 11.1 % higher than the comparable period of the previous year (9M-2015: KEUR 13,823). The reasons for this are the higher business volume and active management of accounts receivable.

The consolidated surplus increased by 4.2 % from KEUR 6,270 (9M-2015) to KEUR 6,533. Earnings per share were EUR 0.40 (9M-2015: EUR 0.40). There were special factors in the tax calculation (capitalization of deferred taxes) in the previous year, which reduced tax expenses according to IFRS. This year, the effects are no longer to be carried in the books, so that tax expenses of KEUR 1,070 are included in the result of the current reporting period.


Cash and cash equivalents including securities amounted to KEUR 20,235 on 30 September 2016 (31 December 2015: KEUR 20,943).

Investments in tangible and intangible assets were made in the amount of KEUR 7,886 in the first nine months of 2016 (9M-2015: KEUR 6,640). This includes investments for the new location of NEXUS headquarters in Donaueschingen. We moved into our new headquarters in July 2016.

Group sales (9 months) in KEUR
+10,5 % as of previous year



Earnings before interest and taxes (9 months) in KEUR
+19,4 % as of previous year



The balance sheet total increased from KEUR 129,691 to KEUR 144,662 (30 September 2016) compared to 31 December 2015. There are no essential bank liabilities. Intangible assets, goodwill and balanced-out deferred taxes add up to a total of KEUR 82,768 following KEUR 74,138 (31 December 2015). Receivables from customers increased slightly from KEUR 20,411 to KEUR 21,170 compared to 31 December 2015.

Employees

NEXUS Group employed a total of 902 people as of 30 September 2016 (30 September 2015: 788 employees). A total of 820 employees (30 September 2015: 726) are employed in the Healthcare Software Division. The Healthcare Service Division employed 82 people (30 September 2015: 62).

Annual Stockholders Meeting and Dividends

At the Annual Stockholders Meeting of NEXUS AG in Stuttgart on 13 May 2016, the Executive Board and Supervisory Board proposed to pay a one cent higher dividend of 0.14 EUR to shareholders than the previous year from the retained earnings of fiscal year 2015. The proposal was adopted by the required majority. Consequently, there was a total distribution of KEUR 2,202.

Finance Highlights 3rd Quarter - 2016

- + 10.5 % increase in sales from KEUR 69,949 (9M-2015) to KEUR 77,308 (9M-2016)
- + 19.4 % increase of EBIT from KEUR 6,341 (9M-2015) to KEUR 7,571 (9M-2016)
- + 11.1 % increase of operative cash flow: KEUR 15,356 (9M-2016) following KEUR 13,823 (9M-2015)
- + € 2.2 million increase in cash and cash equivalents to KEUR 20,235 (30 September 2015: KEUR 18,082).

Sales by division

	01/01/ - 30/09/2016	01/01/ - 30/09/2015	Changes	01/07/ - 30/09/2016	01/07/ - 30/09/2015	Changes
	KEUR	KEUR	%	KEUR	KEUR	%
Healthcare Software	70,905	64,189	10.5	23,163	20,735	11.7
Healthcare Service	6,403	5,760	11.2	2,341	2,163	8.2
Total	77,308	69,949	10.5	25,504	22,898	11.4

Sales by region

	01/01/ - 30/09/2016	01/01/ - 30/09/2015	Changes	01/07/ - 30/09/2016	01/07/ - 30/09/2015	Changes
	KEUR	KEUR	%	KEUR	KEUR	%
Germany	39,380	34,239	15.0	13,782	10,975	25.6
Switzerland	19,939	19,259	3.5	6,235	6,471	-3.6
Netherlands	12,038	10,589	13.7	3,462	3,813	-9.2
France	3,910	3,959	-1.2	1,138	1,249	-8.9
Austria	1,019	1,216	-16.2	474	282	68.1
Other countries	1,022	687	48.8	413	108	> 100
Total	77,308	69,949	10.5	25,504	22,898	11.4

Events after the Balance Sheet Date

With the consent of the Supervisory Board, the Executive Board of NEXUS AG resolved to exercise the authorization granted by the Annual General Meeting of 18 May 2015 to purchase up to 200,000 of its own shares (representing 1.27 % of share capital) of the company pursuant to Section 71 para. 1 No. 8 of the Stock Corporation Act (AktG). The authorization is restricted to the time period until 30 April 2020 and limited to 10 % of the equity capital. The resolution of the Executive Board is designed for the purpose of purchasing own shares of the company one time or several times in line with market conditions and within the context of the Board's authorization to do so.



Your very personal interface.

Individuality is a strength in patient care. Software must be designed to this end. That's why NEXUS / HIS.ng provides the possibility of customizing workspaces. You can easily customize sequence, content and design of your workspace to adapt it to your needs and processes.



NEXUS Group Information and Outlook

Chances and Risks Report

Please refer to the explanations in the annual report of 31 December 2015 for information about the essential chances and risks in the development of NEXUS Group. There have been no essential changes in the meantime.

Outlook: Remain Courageous

We were again able to continue the strong and continuous development of recent years in the first nine months 2016. Sales increased by approx. 10 %, earnings before taxes and interest by approx. 19 %, and the operating cash flow was approx. 11 % higher than in the previous year at € 15 million.

There are still a number of challenges ahead of us for the fourth quarter. Above all, this includes the continuing „launch“ of our NEXT / NEXUS program with the associated marketing and sales activities. In addition, our common development with Olympus will also be launched on the market in the fourth quarter. We have also have to continue integrating the companies acquired over the last 18 months, especially those in other countries. Our positioning as an innovative European eHealth company that achieves growth momentum through the exchange of products, knowledge and technologies between European countries depends strongly on the success of these projects.

As a result, we continue to face a challenging strategic program, in which we must succeed in maintaining a focus on revenues and earnings. This is a path that is associated with considerable risks. However, remaining bold is a prerequisite for continuing our exceptional development.

Accounting and Valuation Methods

This interim report from the NEXUS Group of 30 September 2016 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretations of the International Financial Reporting Interpretation Committee (IFRIC) have been taken into account.

The regulations of IAS 34 were observed in the interim report of 30 September 2016. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Appendix of the Group Financial Statement 2015. The same accounting and valuation methods were used in the Group Financial Statement for the business year 2015.

The report has not been audited.

Directors' Holdings

The director's holders of the Supervisory Board and the Executive Board are as follows on 30 September 2016 in comparison to the previous year: cf. Table.

Supervisory Board	Numbers of stock owned	Numbers of options
Dr. jur. Hans-Joachim König	89,900 Previous year (89,900)	0 Previous year (0)
Prof. Dr. Alexander Pocsay	121,500 Previous year (121,500)	0 Previous year (0)
Prof. Dr. Ulrich Krystek	0 Previous year (0)	0 Previous year (0)
Wolfgang Dörflinger	0 Previous year (0)	0 Previous year (0)
Gerald Glasauer	0 Previous year (0)	0 Previous year (-)
Prof. Dr. med Felicia M. Rosenthal	315 Previous year (0)	0 Previous year (-)

Executive Board	Numbers of stock owned	Numbers of options
Dr. Ingo Behrendt	111,900 Previous year (112,000)	0 Previous year (0)
Ralf Heilig	137,650 Previous year (135,350)	0 Previous year (0)
Edgar Kuner	250,351 Previous year (248,051)	0 Previous year (0)

Capital market, event and finance data

Investor Relations

Active communication with our stockholders, potential investors, analysts and the finance market are the focal point of our investor relation activities. We continually inform all market participants promptly and comprehensively via press releases and ad hoc announcements as well as the mandatory quarterly, semi-annual and annual financial reports.

In addition, we cultivate intensive dialog with institutional investors and finance analysts via telephone conferences, one-on-one meetings and on roadshows. Our Investor Relations team is of course at your disposal as contact persons.

Frankfurt Stock Exchange stock prices (1-year period)



Stock Market Highlights (XETRA closing prices)

- + Initial listing on
4 January 2016: € 18,72
- + Highest price on
05 January 2016: € 19,01
- + Stock Market Price on
30 September 2016: € 18,43
- + Stock market capitalization on
30 September 2016:
€ 290,0 million

11/11/2016

QM Praxistage, Hannover

17/11 - 18/11/2016

IQMG-Jahrestagung, Berlin

25/11/2016

QM Praxistage, Nürnberg

06/12/2016

Personalsoftwareforum, Berlin

13/01 - 15/01/17

Bamberger Morphologietage,
Bamberg

02/02 - 04/02/2017

MR Symposium,
Garmisch-Partenkirchen

19/02 - 23/02/2017

HIMSS, Orlando (USA)

14/03 - 16/03/2017

Zorg & ICT, Utrecht (NL)

29/03 - 30/03/2017

Journées Nationales
Stérilisation, Lyon (F)

08/11/2016

Quarterly Report Q3-2016

21/11 - 23/11/2016

German Equity Forum,
Frankfurt

21/03/2017

Publishing
Annual Report 2016

More IR events for the year 2017 will be announced with the release of the financial report 2016.

Consolidated profit and loss account

for the period from 01 January to 30 September 2016 and 2015

	01/01/ - 30/09/2016	01/01/ - 30/09/2015	01/07/ - 30/09/2016	01/07/ - 30/09/2015
	KEUR	KEUR	KEUR	KEUR
Revenue	77,308	69,949	25,504	22,898
Development work capitalized	3,989	3,542	1,347	1,145
Other operating income	1,302	1,620	653	258
Cost of materials including purchased services	11,656	10,975	4,385	3,779
Personnel costs	45,773	41,154	15,125	13,400
Depreciation	7,025	7,041	2,501	2,402
Other operating expenses	10,574	9,599	2,870	2,662
Operating Result	7,571	6,341	2,623	2,057
Finance Income	57	86	1	8
Finance Expenses	25	24	-65	12
Earnings before Tax on Profit	7,603	6,403	2,689	2,053
Taxes on profit	1,070	133	675	178
Consolidated surplus	6,533	6,270	2,014	1,875
of the consolidated surplus, accounted to:				
• Stockholders of NEXUS AG	6,287	6,275	1,945	1,848
• Shares of non-controlling partners	246	-5	69	27
Consolidated surplus per share in EUR				
Weighted average (undiluted/diluted) of issued shares in circulation (in thousands)	15,718 / 15,761	15,588 / 15,631	15,718 / 15,761	15,588 / 15,631
Undiluted / diluted	0.40 / 0.40	0.40 / 0.40	0.12 / 0.12	0.12 / 0.12

Consolidated profit and loss account

for the period from 01 January to 30 September 2016 and 2015

	01/01/ - 30/09/2016	01/01/ - 30/09/2015	01/07/ - 30/09/2016	01/07/ - 30/09/2015
	KEUR	KEUR	KEUR	KEUR
Consolidated Surplus	6,533	6,270	2,014	1,875
Actuarial profits and losses	-53	-309	-3	365
Tax effects	38	44	-1	-52
Differences from the conversion of foreign currency	-78	1,192	-118	-1,293
Other Overall Result	-93	927	-122	-980
Overall Result of the Period	6,440	7,197	1,892	895
of the overall result of period, accounted to:				
• Stockholders of NEXUS AG	6,194	7,202	1,823	868
• Shares of non-controlling partners	246	-5	69	27

Consolidated Balance Sheet

as of 30 September 2016 and 31 December 2015

Assets	30/09/2016	31/12/2015
	KEUR	KEUR
Long-Term Assets		
Goodwill	46,768	39,126
Other intangible assets	38,367	36,000
Fixed assets	7,751	4,901
Shares in companies valued at equity	31	31
Deferred tax assets	3,417	4,123
Other financial assets	303	297
Total of Long-Term Assets	96,637	84,478
Short-Term Assets		
Inventories	1,216	706
Trade receivables and other receivables	21,170	20,411
Receivables from tax on profits	1,160	702
Other non-financial assets	3,644	2,126
Other financial assets	600	325
Short-term financial assets	2,697	2,744
Cash and balance in bank	17,538	18,199
Total of Short-Term Assets	48,025	45,213
Balance Sheet Total	144,662	129,691

Equity and Liabilities	30/09/2016	31/12/2015
	KEUR	KEUR
Equity Capital		
Subscribed capital	15,736	15,736
Capital reserves	34,249	34,044
Profit carried forward	43,334	37,034
Consolidated surplus	6,287	7,583
Other cumulated Group result	-6,054	-5,042
Own shares	-36	-37
Equity capital attributable to stockholders of the parent company	93,516	89,318
Shares of non-controlling partners	-16	-258
Total Equity Capital	93,500	89,060
Long-Term debts		
Pension obligations	11,023	10,815
Deferred tax liabilities	5,784	5,111
Other financial debts	4,589	1,206
Total of Long-Term Debts	21,396	17,132
Short-Term debts		
Accruals	1,057	938
Financial liabilities	0	14
Trade accounts payable	3,737	4,795
Liabilities from tax on profit	1,812	2,414
Deferred revenue	9,247	3,185
Other non-financial debts	8,384	8,805
Other financial debts	5,529	3,348
Total of Short-Term Debts	29,766	23,499
Balance Sheet Total	144,662	129,691

Consolidated Cash Flow Statement

from 01 January to 30 September 2016 and 2015

	2016	2015
	KEUR	KEUR
1. Cash Flow from Current Business Transactions		
Group annual earnings before tax on income	7,603	6,403
Write-offs (+) / write-ups (-) on intangible assets, tangible assets and financial assets	7,025	7,041
Other expenses not affecting payment (+) / revenue (-)	591	1,133
Increase (-) / decrease (+) in inventories	-280	-291
Gain (-) / loss (+) on disposal of fixed assets and securities	82	32
Increase (-) / decrease (+) in receivables and other assets from operating activities	-509	2,792
Increase (+) / decrease (-) of accruals insofar as not entered in other comprehensive income	-74	-396
Increase (+) / decrease (-) in liabilities from operating activities	1,316	-2,544
Paid interest (-)	-26	-24
Received interest (+)	61	89
Taxes on profit paid (-)	-584	-747
Taxes on profit received (+)	151	335
	15,356	13,823
2. Cash Flow from Investment Activities		
Payments (-) for investments in intangible and fixed assets	-7,886	-6,640
Payments (-) for the acquisition of companies consolidated minus cash acquired	-5,912	-13,995
Receipts (+) from the disposal of short-term financial assets	0	6,000
	-13,798	-14,635
3. Cash Flow from Financing Activities		
Receipts (+) from the issue of new shares in a capital increase	0	8,597
Dividends paid (-)	-2,202	-1,961
Payments (-) for the acquisition of non-controlling interests for already consolidated companies	0	-3,787
Receipts (+) from the sale of own shares	9	59
	-2,193	2,908
Cash relevant changes in cash and cash equivalents (sum of 1 + 2 + 3)	-635	2,096
Exchange rate changes on cash and cash equivalents	-12	-268
Cash and cash equivalents at beginning of period	18,185	13,107
Cash and cash equivalents at end of period	17,538	14,935
Composition of cash and cash equivalents		
Liquid funds	17,538	14,935
	17,538	14,935

Statement of Changes in Consolidated Equity

as of 30 September 2016 and 30 September 2015

	Subscribed capital	Capital reserves	Equity capital difference from currency conversion	Pensions provisions	Profit carried forward	Annual Net Profit - Shortfall	Own Shares	Equity capital attributable to stock of parent company	Shares of non-controlling partners	Equity Capital total	Authorized Capita
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
Consolidated Equity as of 01/01/2015	15,105	25,980	897	-3,971	30,705	8,279	-280	76,715	-903	75,812	6,353
Posting of the consolidated profit 2014 in the Group profit carried forward					8,279	-8,279		0		0	
Actuarial profits and losses				-309				-309		-309	
Deferred taxes entered in other comprehensive income				44				44		44	
Currency differences			1,192		11			1,203	-24	1,179	
Other comprehensive income after taxes 30/09/2015	0	0	1,192	-265	8,290	-8,279	0	938	-24	914	0
Consolidated surplus 9M-2015						6,275		6,275	-5	6,270	
Consolidated surplus	0	0	1,192	-265	8,290	-2,004	0	7,213	-29	7,184	0
Dividend payment					-1,961			-1,961		-1,961	
Purchase / sale of own shares		51					8	59		59	
Capital Increase	631	7,966						8,597		8,597	-631
Purchase of a subsidiary with non-majority shares		-198						-198	150	-48	
Consolidated equity as of 30/09/2015	15,736	33,799	2,089	-4,236	37,034	6,275	-272	90,425	-782	89,643	5,722
Consolidated equity as of 01/01/2016	15,736	34,044	2,585	-7,627	37,034	7,583	-37	89,318	-258	89,060	5,722
Posting of the consolidated profit 2015 in the Group profit carried forward					7,583	-7,583		0		0	
Actuarial profits and losses				-53				-53		-53	
Deferred taxes entered in other comprehensive income				44				44		44	
Currency differences			-1,004	1	919			-84	-4	-88	
Other comprehensive income after taxes 30/09/2016	0	0	-1,004	-8	8,502	-7,583	0	-93	-4	-97	0
Consolidated surplus 9M-2016						6,287		6,287	246	6,533	
Consolidated surplus	0	0	-1,004	-8	8,502	-1,296	0	6,194	242	6,436	0
Dividend payment					-2,202			-2,202		-2,202	
Purchase / sale of own shares		8					1	9		9	
Stock-Based Payment		197						197		197	
Consolidated equity as of 30/09/2016	15,736	34,249	1,581	-7,635	43,334	6,287	-36	93,516	-16	93,500	5,722

Declaration according to § 37y No. 1 WpHG

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Donaueschingen, 08 November 2016

NEXUS AG
The Executive Board

nexus / ag

NEXUS AG, Irmastraße 1, D-78166 Donaueschingen
Registered office of the Company: Villingen-Schwenningen
Phone +49 771 22960-0, Fax +49 771 22960-999
www.nexus-ag.de, info@nexus-ag.de